Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination With Mogamulizumab in Adult Subjects With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 24 Jul 2023
At a glance
- Drugs HTX 201 (Primary) ; Mogamulizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Ovarian cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development
- 10 Apr 2021 Results assessing development of population pharmacokinetics (PK)-pharmacodynamics (PD) model to characterize KHK2455 exposure and its relationship to response in patients with locally advanced or metastatic solid tumors, presented at the 112th Annual Meeting of the American Association for Cancer Research.
- 23 Feb 2021 Status changed from active, no longer recruiting to completed.
- 08 Jan 2020 Planned End Date changed from 1 Aug 2019 to 1 Oct 2020.